Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Withdrawn 7Unknown 5Recruiting 3Completed 3Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 2Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Nasopharyngeal Carcinoma 1Locally Advanced Low Rectal Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1CRC 1Advanced Digestive System Tumor 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 11tislelizumab 9apatinib 8regorafenib 6donafenib 6camrelizumab 5atezolizumab 4Immune Checkpoint Inhibitors 4Hepatectomy 4durvalumab 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2cabozantinib 2anlotinib 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × spartalizumab × Clear all
NCT06364787 2024-04-15

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Beijing 302 Hospital

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06364800 2024-04-15

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Beijing 302 Hospital

Phase EARLY_PHASE1 Not yet recruiting
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡